Industry News, Patient Care

FDA Investigating Reports of Hospitalizations After Fake Ozempic

November 14, 2023
Hospital beds

At least three Americans have been reported hospitalized after using suspected counterfeits of semaglutide drugs, which include Novo Nordisk’s diabetes medication Ozempic, according to records released by the Food and Drug Administration.

Ozempic and Wegovy, another semaglutide medication from Novo Nordisk, have been in short supply for months amid booming sales for their use in weight loss.

The hospitalizations are among 42 reports to the FDA’s Adverse Event Reporting System that mention use of counterfeit semaglutide from around the world. The agency last updated its database at the end of last month to include reports tallied through the end of September.

Read more at CBS News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing